Product details

By continuing to use our site you consent to the use of cookies as described in our privacy policy unless you have disabled them.
You can change your cookie settings at any time but parts of our site will not function correctly without them.
Compact case
Case
-
Reference no. 316-0191-1B
Published by: London Business School
Originally published in: 2018
Version: September 2018
Revision date: 30-Sep-2019
Length: 3 pages
Data source: Field research

Abstract

This is part of a case series. This case series charts the evolution of the hostile battle for Allergan and its ultimate sale to a white knight, Actavis. David Pyott had been the CEO of Allergan since January 1998, only the third CEO in the company's 60+ year history. Allergan was primarily known for Botox, the aesthetic anti-wrinkle product, but the company, which had started out in eye care, had developed Bottox into a USD2 billion multipurpose drug. By 2014 the company, which enjoyed double digit growth, had over 11,000 employees, sold its products in 100 countries and had 40 direct / selling subsidiaries. The business mix included eye care, neurosciences, medical aesthetics, medical dermatology, breast aesthetics and urologics. R&D was the backbone of the company and it had strong cash reserves. In April 2014, it came as a shock to Pyott and the Allergan board that pharma company Valeant in partnership with Pershing Square Capital Management to make a hostile takeover of Allergan.
Location:
Industry:
Other setting(s):
2014

About

Abstract

This is part of a case series. This case series charts the evolution of the hostile battle for Allergan and its ultimate sale to a white knight, Actavis. David Pyott had been the CEO of Allergan since January 1998, only the third CEO in the company's 60+ year history. Allergan was primarily known for Botox, the aesthetic anti-wrinkle product, but the company, which had started out in eye care, had developed Bottox into a USD2 billion multipurpose drug. By 2014 the company, which enjoyed double digit growth, had over 11,000 employees, sold its products in 100 countries and had 40 direct / selling subsidiaries. The business mix included eye care, neurosciences, medical aesthetics, medical dermatology, breast aesthetics and urologics. R&D was the backbone of the company and it had strong cash reserves. In April 2014, it came as a shock to Pyott and the Allergan board that pharma company Valeant in partnership with Pershing Square Capital Management to make a hostile takeover of Allergan.

Settings

Location:
Industry:
Other setting(s):
2014

Related